A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.

Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.

The anti-CD20 monoclonal antibody Arzerra (ofatumumab) has not been recommended for the maintenance therapy of relapsed chronic lymphocytic leukemia (CLL), an expanded indication, by the Committee for Medicinal Products for Human Use (CHMP).

Genmab's anti-CD20 monoclonal antibody drug Arzerra (ofatumumab) has resulted in a low response rate in a single-arm, single-agent Phase II trial testing it as a therapy for relapsed diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma (NHL). However, the company and analysts attributed the "disappointing" result to its use without chemotherapy and a heavily pre-treated population, and a Phase III trial in DLBCL is continuing.